We are preparing the requested document. Please wait, this may take a while...!
|Application / Reactivity||Human||Cow (Bovine)||Mouse (Murine)||Rat (Rattus)||Chicken||Hamster||Monkey|
|Western Blotting (WB)||1561 Antibodies||86 Antibodies||276 Antibodies||222 Antibodies||26 Antibodies||52 Antibodies||102 Antibodies|
|Transfected Cell Culture (TCC)||1 Antibodies|
|RNA Interference (RNAi)||1 Antibodies|
|Radioimmunoassay (RIA)||54 Antibodies||1 Antibodies|
|Proximity Ligation Assay (PLA)||4 Antibodies|
|Intracellular Staining (ICS)||3 Antibodies|
|Antigen||Tumor Protein P53 (TP53) Antibodies|
|Epitope||AA 14-289 Alternatives|
|Reactivity||Chicken, Cow (Bovine), Hamster, Human, Monkey, Mouse (Murine), Rat (Rattus) Alternatives|
|Conjugate||This p53 antibody is un-conjugated Alternatives|
Immunohistochemistry (Frozen Sections) (IHC (fro)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunoprecipitation (IP), Western Blotting (WB)
|7 references available|
|Supplier||Log in to see|
Product Details anti-p53 AntibodyTarget Details p53 Application Details Handling References for anti-p53 Antibody (ABIN967419) Images
|Cross-Reactivity||Mouse (Murine), Rat (Rattus), Hamster, Monkey, Cow (Bovine), Chicken|
1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
2. Please refer to us for technical protocols.
3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
|Purification||The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.|
|Immunogen||Human p53 aa. 14-289|
Target Details p53Product Details anti-p53 Antibody Application Details Handling References for anti-p53 Antibody (ABIN967419) Images back to top
|Alternative Name||p53 (TP53 Antibody Abstract)|
P53 is a nuclear phosphoprotein which acts as a tumor suppressor by providing a cell cycle checkpoint for DNA damage during S-phase. Mutations in wildtype p53 can indirectly alter the DNA binding and transcription factor activity of p53. By altering expression of genes normally regulated by p53, these mutations can result in both a loss of tumor suppressor function and a gain of oncogenic function. The majority of mutations in the p53 gene are missense mutations which alter the identity of an amino acid. These mutations may alter the conformation and thus increase the stability of the mutant p53 protein. p53 is expressed in all vertebrate species examined. p53 may be overexpressed in transformed cell lines, where it forms complexes with viral oncogenes including SV40 large T antigen and the adenovirus protein, E1B. p53 migrates at ~53 kDa on SDS-PAGE.
PAb 240 reacts with a conformational epitope between amino acids 156 and 214 of native p53. As such, Pab 240 recognizes only certain mutant forms of p53, as determined by immunoprecipitation. It detects both mutant and wildtype p53 in western blot analysis and immunohistochemistry of frozen tissue sections. It is thought that p53 mutations exert a common conformational change which results in expression of the Pab 240-specific epitope on mutant p53 molecules. A recombinant fusion protein of p53 sequence including amino acids 14-289 was used as immunogen.
|Molecular Weight||53 kDa|
|Research Area||Cancer, Cell Cycle, Transcription Factors, DNA/RNA, Apoptosis/Necrosis|
|Pathways||p53 Signaling, MAPK Signaling, PI3K-Akt Signaling, Apoptosis, AMPK Signaling|
Application DetailsProduct Details anti-p53 Antibody Target Details p53 Handling References for anti-p53 Antibody (ABIN967419) Images back to top
|Application Notes||SV40-transformed COS-7 monkey kidney cells (ATCC CRL-1651) or other SV40-transformed cell lines are suggested as positive controls.|
|Restrictions||For Research Use only|
HandlingProduct Details anti-p53 Antibody Target Details p53 Application Details References for anti-p53 Antibody (ABIN967419) Images back to top
|Buffer||Aqueous buffered solution containing ≤0.09 % sodium azide.|
|Precaution of Use||This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.|
|Storage Comment||Store undiluted at 4°C.|
References for anti-p53 Antibody (ABIN967419)Product Details anti-p53 Antibody Target Details p53 Application Details Handling Images back to top
|Product cited in:||
Jacquemier, Molès, Penault-Llorca, Adélaide, Torrente, Viens, Birnbaum, Theillet: "p53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: comparison of staining and PCR-SSCP results." in: British journal of cancer, Vol. 69, Issue 5, pp. 846-52, 1994
Said, Barrera, Shintaku, Nakamura, Koeffler: "Immunohistochemical analysis of p53 expression in malignant lymphomas." in: The American journal of pathology, Vol. 141, Issue 6, pp. 1343-8, 1993
Moore, Teresky, Levine, Seiberg: "p53 mutations are not selected for in simian virus 40 T-antigen-induced tumors from transgenic mice." in: Journal of virology, Vol. 66, Issue 2, pp. 641-9, 1992
Walker, Dearing, Lane, Varley: "Expression of p53 protein in infiltrating and in-situ breast carcinomas." in: The Journal of pathology, Vol. 165, Issue 3, pp. 203-11, 1992
Bártek, Bártková, Vojt?sek, Stasková, Lukás, Rejthar, Kovarík, Midgley, Gannon, Lane: "Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies." in: Oncogene, Vol. 6, Issue 9, pp. 1699-703, 1991
Vojt?sek, Bártek, Midgley, Lane: "An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53." in: Journal of immunological methods, Vol. 151, Issue 1-2, pp. 237-44, 1992
Gannon, Greaves, Iggo, Lane: "Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form." in: The EMBO journal, Vol. 9, Issue 5, pp. 1595-602, 1990
ImagesProduct Details anti-p53 Antibody Target Details p53 Application Details Handling References for anti-p53 Antibody (ABIN967419) back to top